Promising Results for Ziresovir in Treating Respiratory Syncytial Virus in Infants

Findings from a recent phase 3 trial indicate that ziresovir may soon be approved for the treatment of respiratory syncytial virus (RSV) in infants. This development could offer a new therapeutic option for managing RSV, a common and sometimes severe respiratory infection in young children. The trial's results are a significant step forward in the fight against RSV, highlighting the potential of ziresovir to improve outcomes for affected infants.